Tg Therapeutics (TGTX) Free Cash Flow (2011 - 2026)

Tg Therapeutics' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$17.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 37.56% year-over-year to -$17.9 million; the TTM figure through Mar 2026 stood at -$14.2 million (up 76.77% YoY), while the FY2025 annual figure was -$25.0 million, up 38.4% from the prior year.
• Free Cash Flow was -$17.9 million for Q1 2026 at Tg Therapeutics, down from $19.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $83.7 million in Q3 2023 to a low of -$68.7 million in Q1 2022.
• Historically, Free Cash Flow has averaged -$17.1 million across 5 years, with a median of -$23.2 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow soared 342.63% in 2023, then slumped 250.19% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$23.9 million in 2022, then soared by 44.67% to -$13.2 million in 2023, then slumped by 94.26% to -$25.7 million in 2024, then surged by 176.35% to $19.6 million in 2025, then plunged by 191.59% to -$17.9 million in 2026.
• The last three Free Cash Flow figures came in at -$17.9 million (Q1 2026), $19.6 million (Q4 2025), and -$23.2 million (Q3 2025), per Business Quant data.